THE EFFECT OF ANTI-PD-1 THERAPY ON MEDIAN OVERALL SURVIVAL AND PROGRESSION FREE SURVIVAL IN GLIOBLASTOMA MULTIFORME PATIENTS WITH CERTAIN TUMOR MARKERS

被引：1
|
作者：
Paracha, Awais [1 ]
Campian, Jian [2 ]
机构：
[1] St Louis Univ, Sch Med, St Louis, MO USA
[2] Washington Univ, St Louis, MO 63110 USA
来源：
JOURNAL FOR IMMUNOTHERAPY OF CANCER | 2020年 / 8卷
关键词：
D O I：
10.1136/jitc-2020-SITC2020.0214
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
214
引用
收藏
页码：A128 / A128
页数：1
相关论文
共 50 条
  • [21] MRI Biomarkers of Bevacizumab Therapy Correlate with Progression-Free Survival but Not Overall Survival in Recurrent Glioblastoma
    Dillon, William P.
    RADIOLOGY, 2020, 297 (01) : 176 - 177
  • [22] Association of immune-related adverse events (irAEs) with improved response, progression-free survival, and overall survival for patients with metastatic head and neck cancer receiving anti-PD-1 therapy.
    Foster, Corey Christian
    Kochanny, Sara
    Khattri, Arun
    Acharya, Rajesh
    Dekker, Allison
    Tan, Yi-Hung Carol
    Klema, Elaine
    Brisson, Ryan J.
    Saloura, Vassiliki
    Pearson, Alexander T.
    Vokes, Everett E.
    Leidner, Rom S.
    Mehanna, Hisham Mohamed
    Seiwert, Tanguy Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [23] Neoadjuvant Anti-PD-1 Immunotherapy Leads to Survival Benefit in Recurrent Glioblastoma
    Newman, W. Christopher
    Amankulor, Nduka M.
    NEUROSURGERY, 2019, 85 (02) : E190 - E191
  • [24] The effect of extent of resection on time to tumor progression and survival in patients with glioblastoma multiforme of the cerebral hemisphere - Commentary
    Shapiro, WR
    SURGICAL NEUROLOGY, 1999, 52 (04): : 379 - 379
  • [25] Expression of markers of neural stem and progenitor cells in glioblastoma multiforme in relation to tumor recurrence and overall survival
    Wankowicz, Pawel
    Roginska, Dorota
    Machalinski, Boguslaw
    Nowacki, Przemyslaw
    ARCHIVES OF MEDICAL SCIENCE, 2020, 16 (02) : 481 - 483
  • [26] Preoperative Tumor Growth Rate Does Not Predict Overall or Progression-free Survival in Patients With Glioblastoma
    Leppert, Jan
    Ditz, Claudia
    Matschke, Jakob
    Matone, Maria Vittoria
    Kuppler, Patrick
    Hillbricht, Christina
    Krenzlin, Harald
    Keric, Naureen
    Schacht, Hannes
    Ziemann, Christian
    Groh, Elisa Maria
    Liubich, Larysa
    Zemskova, Oksana
    Rades, Dirk
    Loeser, Anastassia
    ANTICANCER RESEARCH, 2024, 44 (11) : 5043 - 5049
  • [27] Extended adjuvant temozolamide as prognostic factor of longer overall and progression-free survival in glioblastoma multiforme
    Povoa, S. C.
    Tavares, N.
    Ribeiro, M. J.
    Azevedo, D.
    Coelho, A.
    Fernandes, A.
    Costa, A.
    Caeiro, C.
    Carvalho, B.
    Linhares, P.
    Osorio, L.
    Castro, L.
    Fonseca, J.
    Damasceno, M.
    ANNALS OF ONCOLOGY, 2016, 27
  • [28] Immune-related adverse events are linked with improved progression-free survival in patients receiving anti-PD-1/PD-L1 therapy
    Shafqat, Hammad
    Gourdin, Theodore
    Sion, Amy
    SEMINARS IN ONCOLOGY, 2018, 45 (03) : 156 - 163
  • [29] Progression-free survival, post-progression survival, and tumor response as surrogate markers for overall survival in patients with extensive small cell lung cancer
    Imai, Hisao
    Mori, Keita
    Wakuda, Kazushige
    Ono, Akira
    Akamatsu, Hiroaki
    Shukuya, Takehito
    Taira, Tetsuhiko
    Kenmotsu, Hirotsugu
    Naito, Tateaki
    Kaira, Kyoichi
    Murakami, Haruyasu
    Endo, Masahiro
    Nakajima, Takashi
    Yamamoto, Nobuyuki
    Takahashi, Toshiaki
    ANNALS OF THORACIC MEDICINE, 2015, 10 (01) : 61 - 66
  • [30] The value of quantitative pentavalent 99mTc-dimercaptosuccinic acid scan in predicting progression-free survival and overall survival in patients with glioblastoma multiforme
    Saad, Ehab
    Badawy, Ahmed
    Abougabal, Mahasen
    Kandeel, Ahmed
    JOURNAL OF RADIOTHERAPY IN PRACTICE, 2021, 20 (02) : 203 - 209
12345